Johns Hopkins ABX Guide
Omadacycline
INDICATIONS
FDA
FDA
Treatment of adult patients with the following infections caused by susceptible microorganisms:
- Community-acquired bacterial pneumonia (CABP)
- Acute bacterial skin and skin structure infections (ABSSSI)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 8, 2022
Citation
Avdic, Edina. "Omadacycline." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540708/all/Omadacycline.
Avdic E. Omadacycline. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540708/all/Omadacycline. Accessed December 26, 2024.
Avdic, E. (2022). Omadacycline. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540708/all/Omadacycline
Avdic E. Omadacycline [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 December 26]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540708/all/Omadacycline.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Omadacycline
ID - 540708
A1 - Avdic,Edina,Pharm.D.
Y1 - 2022/01/08/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540708/all/Omadacycline
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
